The use of real-world evidence is now commonplace but not all real-world evidence is equal and, in the race to deliver an evidence plan, sometimes sight is lost of the ultimate utility of the data.
This article covers some of the key themes to make sure your evidence plan meets stakeholder needs.
Comparing the costs of Dravet syndrome and how these are affected by disease severitys
Read our article which takes new real world evidence and compares cohorts of patients with Dravet syndrome and their carers.
Proposed changes to government supported reimbursement of pharmaceuticals has opened up the possibility of international reference pricing for the US.
This article covers the issues and potential unintended consequences of opening the genies bottle of international referencing for the US market.
Early economic modelling can deliver insights and inputs into clinical development
Read our article on approaches to early economic modelling, its role beyond setting a price expectation and some of the core issues in developing effective early economic models.
Simple estimates of prevalence based on current incidence may dramatically overestimate patient populations in rarer diseases.
This article covers the key drivers of differences between observed prevalence and a calculated maximum prevalence based on a series of drag factors.
The need for different healthstates
Read our article on approaches to new structural solutions for modelling immuno-oncology. A stepwise approach to ensuring that model structures reflect clinical reality.
Overall survival and decisions on modelling the tail of the curve
Read our article on approaches to data and modelling for immuno-oncology. Building a structured and robust framework to assess products with new and transformative modes of action.
Willingness to pay is a commonly used approach to assessing value for money
Read our article on who pays for healthcare and how they pay. The answer can be diverse, complex and sometimes obscure.
Can a focus on quality of life be misplaced?
We discuss why utility measurements can be complex and at times misleading.
Health technology assessment for orphan drugs continues to present challenges for pharmaceutical companies.
This article covers who reviews orphan drugs and when, and how to optimise your market access strategy.
A new open access to clinical trials data, coupled with enhanced real world patient records bring the potential for new metrics of value, a better understanding of comparators and the opportunity for new modes of pricing.
This article covers the opportunities and challenges of this new open access to data.
In an era of population growth, population aging and the seemingly inevitable expansion of chronic conditions (such as diabetes) the spotlight is more than ever before on health service budgets.
This article covers how much does healthcare cost, where does all the money go and does spending matter.
Below are links to our privacy policies